Egla Hasimllari, PharmD

This new drug utilizes the bactericidal properties of taurolidine and the bloodthinning effects of heparin to maintain catheter patency.

On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.

Oteseconazole is a treatment option for those living with a previously unmet medical need.